Clinical trials of PARP inhibitors have made continuous progress in solid tumors such as breast cancer, ovarian cancer and pancreatic cancer, but the problem of drug resistance of PARP inhibitors has gradually emerged, and one of the solutions is drug combination (Lee and Matulonis, 2020; Li et al., 2020). Here, PARP1 is linked to breast cancer.